Correction to: BRAF Inhibitor Resistance in Meslanoma: Mechanisms and Alternative Therapeutic Strategies
- PMID: 36459337
- PMCID: PMC9767990
- DOI: 10.1007/s11864-022-01038-z
Correction to: BRAF Inhibitor Resistance in Meslanoma: Mechanisms and Alternative Therapeutic Strategies
Conflict of interest statement
This work was supported by Shanghai Science and Technology Development Funds (19411951700), the Lingang Laboratory (Grant No. LG-QS-202205-11), and the national natural science foundation of China (81802636).
JZ wrote and edited this manuscript and created tables and figure. JZ, ZZ, WS, WY, CW, WL, XL, and YC reviewed and revised the manuscript. WS and YC provided direction and guidance throughout the preparation of the manuscript. All authors read and approved the final manuscript.
The original article has been corrected.
Erratum for
-
BRAF Inhibitor Resistance in Melanoma: Mechanisms and Alternative Therapeutic Strategies.Curr Treat Options Oncol. 2022 Nov;23(11):1503-1521. doi: 10.1007/s11864-022-01006-7. Epub 2022 Oct 1. Curr Treat Options Oncol. 2022. PMID: 36181568 Free PMC article. Review.
Publication types
LinkOut - more resources
Full Text Sources
Research Materials